George A Fisher, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 5
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
5 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fisher’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
5 of 5 plans
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence G65330 · Current
Licensed to practise in California · since 1989 · expires 2027-03-31 · Stanford University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$71,940
Medicare paid this office $71,940 for 201 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 127 | $46,500 | $171 |
| Long return visit (40+ min) | 39 | $7,324 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,087 | $105 |
| Return visit (30+ min) | 30 | $3,972 | $120 |
| New patient visit (60+ min) | 18 | $3,395 | $189 |
See all 6 services
| Long return visit (40+ min) | 127 | $46,500 | $171 |
| Long return visit (40+ min) | 39 | $7,324 | $128 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 17 | $4,087 | $105 |
| Return visit (30+ min) | 30 | $3,972 | $120 |
| New patient visit (60+ min) | 18 | $3,395 | $189 |
| New patient visit (60+ min) | 11 | $1,790 | $163 |
Who their Medicare patients are
201 Original Medicare patients in 2024. Average age 75 · Women 42% · Also on Medicaid 16% · Health risk score 2.27. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 69% · Cancer 50% · Diabetes 34% · Coronary heart disease 28% · Chronic kidney disease 26% · Atrial fibrillation 22% · Heart failure 14% · Depression 13% · COPD 9% · Stroke 9% · Dementia 5%.
The office billed $356,038, Medicare allowed $91,330 and paid $71,940; for 474 services of 12 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 201 | 474 | 75 | 2.27 | $356,038 | $71,940 |
| 2023 | 237 | 598 | 74 | 2.08 | $435,504 | $76,244 |
| 2022 | 233 | 586 | 74 | 2.16 | $438,685 | $74,497 |
| 2021 | 281 | 862 | 72 | 2.19 | $601,838 | $107,534 |
| 2020 | 250 | 715 | 73 | 2.20 | $367,554 | $73,412 |
| 2019 | 282 | 835 | 72 | 2.23 | $166,636 | $81,517 |
| 2018 | 263 | 697 | 72 | 2.32 | $142,598 | $68,381 |
| 2017 | 254 | 696 | 72 | 2.56 | $181,489 | $66,887 |
| 2016 | 284 | 807 | 72 | 2.28 | $234,179 | $74,216 |
| 2015 | 233 | 664 | 73 | 2.21 | $179,993 | $59,269 |
| 2014 | 287 | 823 | 72 | 1.97 | $223,093 | $74,821 |
| 2013 | 288 | 724 | 73 | 2.02 | $198,941 | $63,938 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 171 | $51,977 | $129 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 27 | $8,551 | $110 |
| New patient visit (60+ min) | 45 | $7,436 | $165 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,558 | $155 |
| Hospital discharge day management, more than 30 minutes | 12 | $1,392 | $107 |
| Return visit (30+ min) | 13 | $1,174 | $90 |
2022: 4 services
| Long return visit (40+ min) | 167 | $53,786 | $132 |
| New patient visit (60+ min) | 50 | $8,618 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 14 | $4,162 | $95 |
| Return visit (30+ min) | 37 | $3,537 | $86 |
2021: 8 services
| Long return visit (40+ min) | 170 | $67,756 | $136 |
| Return visit (30+ min) | 92 | $11,751 | $90 |
| New patient visit (60+ min) | 66 | $11,440 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $5,632 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,305 | $179 |
| Hospital discharge day management, more than 30 minutes | 16 | $1,601 | $100 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,555 | $65 |
| Short return visit (20+ min) | 14 | $960 | $53 |
2020: 7 services
| Long return visit (40+ min) | 138 | $39,722 | $104 |
| New patient visit (60+ min) | 65 | $10,200 | $157 |
| Return visit (30+ min) | 70 | $7,145 | $72 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 24 | $5,718 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,655 | $192 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,684 | $99 |
| Short return visit (20+ min) | 13 | $1,050 | $48 |
2019: 8 services
| Long return visit (40+ min) | 141 | $39,849 | $100 |
| New patient visit (60+ min) | 65 | $9,900 | $152 |
| Return visit (30+ min) | 76 | $8,612 | $71 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 41 | $8,301 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,873 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $5,149 | $65 |
| Hospital discharge day management, more than 30 minutes | 19 | $1,884 | $99 |
| Hospital discharge day management, 30 minutes or less | 11 | $743 | $68 |
2018: 7 services
| Long return visit (40+ min) | 120 | $31,138 | $98 |
| New patient visit (60+ min) | 77 | $11,252 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $7,677 | $92 |
| Return visit (30+ min) | 72 | $7,164 | $70 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,640 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,288 | $65 |
| Hospital discharge day management, 30 minutes or less | 16 | $1,070 | $67 |
2017: 7 services
| Long return visit (40+ min) | 122 | $33,012 | $98 |
| Return visit (30+ min) | 70 | $7,188 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 29 | $7,104 | $93 |
| New patient visit (60+ min) | 45 | $6,621 | $147 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,170 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 28 | $3,628 | $65 |
| Hospital discharge day management, more than 30 minutes | 20 | $1,964 | $98 |
2016: 8 services
| Long return visit (40+ min) | 145 | $37,904 | $95 |
| Return visit (30+ min) | 86 | $9,666 | $65 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $7,778 | $93 |
| New patient visit (60+ min) | 41 | $5,911 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 29 | $5,588 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $1,929 | $64 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,070 | $97 |
| Hospital discharge day management, 30 minutes or less | 13 | $855 | $66 |
2015: 7 services
| Long return visit (40+ min) | 117 | $31,166 | $94 |
| Return visit (30+ min) | 96 | $9,647 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $4,741 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 21 | $4,519 | $181 |
| New patient visit (60+ min) | 30 | $4,498 | $150 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $1,425 | $65 |
| Short return visit (20+ min) | 20 | $909 | $43 |
2014: 8 services
| Long return visit (40+ min) | 127 | $35,245 | $98 |
| Return visit (30+ min) | 121 | $13,153 | $66 |
| New patient visit (60+ min) | 53 | $7,765 | $147 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 38 | $7,209 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 26 | $4,856 | $180 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $2,050 | $64 |
| Short return visit (20+ min) | 35 | $1,852 | $43 |
| Hospital discharge day management, more than 30 minutes | 11 | $1,062 | $97 |
2013: 6 services
| Long return visit (40+ min) | 132 | $26,928 | $93 |
| Return visit (30+ min) | 111 | $12,306 | $65 |
| New patient visit (60+ min) | 69 | $9,916 | $144 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,708 | $173 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 22 | $4,152 | $90 |
| Short return visit (20+ min) | 43 | $2,163 | $38 |
Medicaid work
$5,323 in 2024
Medicaid paid $5,323 for 87 billed services this clinician did in 2024, up to 17 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 50 | $4,151 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 37 | $1,172 |
| 2024 | 87 | 2 | 17 | $5,323 |
| 2023 | 150 | 1 | 18 | $6,534 |
| 2022 | 55 | 1 | 13 | $3,258 |
| 2020 | 14 | 1 | 13 | $1,143 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 150 | $6,534 |
2022
| Long return visit (40+ min) | 55 | $3,258 |
2020
| 1ST HOSP IP/OBS HIGH 75 | 14 | $1,143 |
Money from drug and device companies
$53 in 2025
| 2025 | 1 | 1 | None | $53 |
| 2024 | 2 | 10 | $3,000 | $4,763 |
| 2023 | 3 | 4 | $2,966 | $4,280 |
| 2022 | 6 | 12 | $19,244 | $19,371 |
| 2021 | 3 | 4 | $5,781 | $5,906 |
| 2020 | 6 | 11 | $14,519 | $15,777 |
| 2019 | 4 | 37 | $36,894 | $56,285 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genentech | None | $53 | 1 payment
|
See the published payment
| Genentech | Education · 2025-10-04 | None | $53 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $4,763
| Exelixis | Cabometyx | $4,716 | 9 payments
|
| E.R. Squibb & Sons L.L.C. | None | $47 | 1 payment
|
2023: $4,280
| AstraZeneca UK | Imfinzi | $2,966 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | None | $1,258 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $56 | 1 payment
|
2022: $19,371
| AstraZeneca UK | Imfinzi | $5,994 | 4 payments
|
| Merck Sharp & Dohme | None | $4,270 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $3,277 | 4 payments
|
| Genentech | None | $2,850 | 1 payment
|
| F. Hoffmann-La Roche AG | Tecentriq | $1,980 | 1 payment
|
| Taiho Oncology | Lonsurf | $1,000 | 1 payment
|
2021: $5,906
| AstraZeneca UK | None | $4,281 | 2 payments
|
| Merck Sharp & Dohme | None | $1,500 | 1 payment
|
| Novartis Pharmaceuticals | Lutathera | $125 | 1 payment
|
2020: $15,777
| AstraZeneca AB | None | $6,717 | 1 payment
|
| AstraZeneca UK | None | $4,453 | 2 payments
|
| Merck Sharp & Dohme | None | $1,850 | 2 payments
|
| Advanced Accelerator Applications | Lutathera | $1,500 | 1 payment
|
| Hoffmann-La Roche | Non-Covered Product | $1,230 | 4 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $28 | 1 payment
|
2019: $56,285
| Merck Sharp & Dohme | None | $28,896 | 26 payments
|
| Terumo Medical | None | $24,758 | 5 payments
|
| Taiho Oncology | Tas-102 | $2,569 | 5 payments
|
| Genentech | Non-Covered Product | $62 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2022 | Their institution | $299,672 |
| Genentech, Inc. · Ph Ib Personalized Cancer Vaccine Atezolizumabb · 2019 | Their institution | $139,154 |
| Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2020 | Their institution | $123,587 |
| Genentech, Inc. · Intrinsic Mcrc With Specific Genomic Alterations · 2025 | Their institution | $101,627 |
| Genentech, Inc. · Phib Study of Ro6958688 and Atezolizumab in 3l Mss Mcrc Pts After Pretx With Obinutuzumab · 2020 | Their institution | $89,540 |
| Genentech, Inc. · Ph Ib Personalized Cancer Vaccine Atezolizumabb · 2020 | Their institution | $71,730 |
| Genentech, Inc. · Open Label Dose Escalation Study Safety Pk of Atezolizumab · 2019 | Their institution | $66,011 |
| Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2024 | Their institution | $59,021 |
| Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2019 | Their institution | $45,521 |
| Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2021 | Their institution | $37,405 |
| Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2023 | Their institution | $18,768 |
| Genentech, Inc. · Atezolizumab P1b Combo Atezo and Antivegf Therapies With Solid Tumors · 2021 | Their institution | $17,738 |
| Merck Sharp & Dohme LLC · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2022 | Their institution | $11,963 |
| Genentech, Inc. · Eih Pre Lip Mad in Pts · 2020 | Their institution | $9,788 |
| Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2024 | Their institution | $7,484 |
| Merck Sharp & Dohme LLC · A Phase III Study of Pembrolizumab Mk-3475 Vs. Chemotherapy in Microsatellite Instability-High Msi-H Or Mismatch Repair Deficient Dmmr Stage IV Colorectal Carcinoma Keynote-177 · 2022 | Their institution | $7,315 |
| Genentech, Inc. · Intrinsic Mcrc With Specific Genomic Alterations · 2024 | Their institution | $7,285 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2019 | Their institution | $5,235 |
| Merck Sharp & Dohme Corporation · A Phase III Study of Pembrolizumab Vs Chemotherapy in Microsatellite Instability- High Or Mismatched Repair Deficient Colorectal Carcinoma · 2021 | Their institution | $3,558 |
| Genentech, Inc. · Eih Pre Lip Mad in Pts · 2021 | Their institution | $3,488 |
| Genentech, Inc. · Ph Ia Ib Personalized Cancer Vaccine Atezolizumabb · 2021 | Their institution | $3,450 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2021 | Their institution | $1,559 |
| Merck Sharp & Dohme Corporation · A Phase II Study of Pembrolizumab Mk-3475 As Monotherapy in Subjects With Previously Treated Locally Advanced Unresectable Or Metastatic Stage IV Mismatched Repair Deficient Or Microsatellite Instability-High Colorectal Carcinoma Keynote-164 · 2020 | Their institution | $1,459 |
| Genentech, Inc. · Eih Pre Lip Mad in Pts · 2019 | Their institution | $1,280 |
| Genentech, Inc. · Cea Tcb Phase 1b Combination With Apd L1 Study · 2020 | Their institution | $530 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1255446308
- Licence
- CA G65330California G65330: Current · expires 2027-03-31
- Trained
- Stanford University School of Medicine, 1987
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G653300
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 2680 Hanover St, Palo Alto, CA, 94304
- NPI first listed
- 2006-08-20
- NPI last updated
- 2009-02-27
This is when the NPI record was last certified, not a medical board exam.